The effects of the immunosuppressants cyclosporin A (CsA) and tacrolimus (FK506) on the IL-1␤-induced matrix metalloproteinase-9 (MMP-9) were investigated. Impairment of the protease-antiprotease balance contributes to renal fibrosis, which is observed collectively under long-term treatment with either immunosuppressant. It is demonstrated that CsA, in contrast to FK506, reduced the IL-1␤-induced MMP-9 content in conditioned media of mesangial cells, which coincides with a reduction in the cytokine-induced MMP-9 mRNA level. Similar to FK506, the VIVIT peptide, a specific inhibitor of the nuclear factor of activated T cells, did not affect the cytokine-induced MMP-9 level. Moreover, CsA caused a dose-dependent inhibition on the IL-1␤-induced luciferase activity of a T he calcineurin inhibitors cyclosporin A (CsA) and FK506 are among the most potent immunosuppressant drugs that are used for the treatment of many kidney diseases. However, their clinical use is accompanied by severe adverse effects, among which nephrotoxicity that causes glomerulosclerosis and interstitial fibrosis are most common (for review, see reference [1]). Mechanistically, the immunosuppressive potency of both drugs is achieved mainly through an inhibition of the protein phosphatase calcineurin, which is critically involved in IL-2 production by T lymphocytes by the action of the nuclear factor of activated T cells (NFAT) (for review, see references [2, 3] ). Different NFAT have been identified not only in cells from lymphoid origin but also in a variety of nonlymphoid tissues and cell types (3,4). Moreover, despite NFAT inhibition, other mechanisms are likely to play an important role. Both immunosuppressants can inhibit the expression of various proinflammatory genes, including inducible nitric oxide synthase (5), secretory phospholipase type A 2 (6), and inducible cyclooxygenase II (7) primarily via a modulation of the ubiquitously expressed transcription factors NF-B and activator protein-1 (AP-1) (8,9). In contrast to the anti-inflammatory activities, the primary mode of fibrosis that is induced by either immunosuppressant is reflected by an excessive deposition of extracellular matrix (ECM), which predominantly results from an imbalance between proteins that regulate ECM turn over. Physiologically, degradation of ECM proteins is guaranteed by the action of matrix metalloproteinases (MMP) and their intrinsic inhibitors, the tissue inhibitors of MMP. In addressing CsA-induced renal fibrosis, so far most attention has focused on the protease inhibitors, whereas less attention has been drawn to the MMP system itself (10,11). However MMP, particularly MMP-9, are crucially involved in the progression of renal fibrosis. In the kidney, under inflammatory conditions, this MMP subtype is highly expressed in renal mesangial cells (MC), a cell type that is considered one of the main cellular targets of CsA-induced nephrotoxicity (12,13). Functional promoter elements that are necessary for cytokinedependent promoter activation lie within a 1.3-kb fragment of the rat MMP-9 gene and include binding sites for AP-1 and NF-B (14 -16). The activity of both transcription factors is controlled by members of the mitogen-activated protein kinase (MAPK) family, including the c-Jun N-terminal kinase (JNK), the p38 MAPK, and the extracellular signal-regulated kinase Received June 7, 2006. Accepted November 9, 2006 Published online ahead of print. Publication date available at www.jasn.org.
T he calcineurin inhibitors cyclosporin A (CsA) and FK506 are among the most potent immunosuppressant drugs that are used for the treatment of many kidney diseases. However, their clinical use is accompanied by severe adverse effects, among which nephrotoxicity that causes glomerulosclerosis and interstitial fibrosis are most common (for review, see reference [1] ). Mechanistically, the immunosuppressive potency of both drugs is achieved mainly through an inhibition of the protein phosphatase calcineurin, which is critically involved in IL-2 production by T lymphocytes by the action of the nuclear factor of activated T cells (NFAT) (for review, see references [2, 3] ). Different NFAT have been identified not only in cells from lymphoid origin but also in a variety of nonlymphoid tissues and cell types (3, 4) . Moreover, despite NFAT inhibition, other mechanisms are likely to play an important role. Both immunosuppressants can inhibit the expression of various proinflammatory genes, including inducible nitric oxide synthase (5), secretory phospholipase type A 2 (6) , and inducible cyclooxygenase II (7) primarily via a modulation of the ubiquitously expressed transcription factors NF-B and activator protein-1 (AP-1) (8, 9) . In contrast to the anti-inflammatory activities, the primary mode of fibrosis that is induced by either immunosuppressant is reflected by an excessive deposition of extracellular matrix (ECM), which predominantly results from an imbalance between proteins that regulate ECM turn over. Physiologically, degradation of ECM proteins is guaranteed by the action of matrix metalloproteinases (MMP) and their intrinsic inhibitors, the tissue inhibitors of MMP. In addressing CsA-induced renal fibrosis, so far most attention has focused on the protease inhibitors, whereas less attention has been drawn to the MMP system itself (10, 11) . However MMP, particularly MMP-9, are crucially involved in the progression of renal fibrosis. In the kidney, under inflammatory conditions, this MMP subtype is highly expressed in renal mesangial cells (MC), a cell type that is considered one of the main cellular targets of CsA-induced nephrotoxicity (12, 13) . Functional promoter elements that are necessary for cytokinedependent promoter activation lie within a 1.3-kb fragment of the rat MMP-9 gene and include binding sites for AP-1 and NF-B (14 -16) . The activity of both transcription factors is controlled by members of the mitogen-activated protein kinase (MAPK) family, including the c-Jun N-terminal kinase (JNK), the p38 MAPK, and the extracellular signal-regulated kinase (ERK) (14) . These MAPK can be activated by proinflammatory cytokines such as IL-1␤ and TNF-␣, although the cellular response of MAPK activation is highly divergent and depends on the cell type investigated (17, 18) .
Pharmacologically, the immunosuppressive activity of FK506 has been reported to be 50 to 100 times higher than CsA (19 -21) but exerts a lower fibrogenic influence on glomeruli. Therefore, the renal dysfunctions that accompany FK506 treatment in some cases were less severe than those that were observed under CsA treatment (22, 23) . With respect to their different profibrotic potential, this study compared the modulatory effects and underlying mechanisms of both immunosuppressive agents on the cytokine-induced MMP-9 expression in glomerular MC with a special focus drawn to the signaling pathways that are critically involved in the transcriptional control of MMP-9.
Materials and Methods

Reagents
Human recombinant IL-1␤ was received from Cell Concept (Umkirch, Germany). The calcium ionophore ionomycin was purchased from Sigma-Aldrich Chemie (Taufkirchen, Germany). The VIVIT peptide, PD98059, SB203580 and SP600125, dexamethasone, and cycloheximide were purchased from Calbiochem (Schwalbach, Germany). The immunosuppressive drugs CsA and FK506 were purchased from Alexis Biochemicals (Grü nberg, Germany). Antibodies against p65 (sc-109), c-fos (sc-52), c-jun (sc-45), Jun B (sc-46), and IB␣ (sc-371), as well as the anti-rabbit and anti-mouse horseradish peroxidaselinked IgG were purchased from Santa Cruz Biotechnology (Heidelberg, Germany). Antibodies against phosphorylated and total ERK, JNK, and p38-MAPK were obtained from Cell Signaling (Frankfurt am Main, Germany). [␣-
32 P]dCTP (specific activity 3000 Ci/mmol) and [␣-32 P]dATP (specific activity 3000 Ci/mmol), the ECL system, and
Hyperfilm were purchased from Amersham Pharmacia Biotech (Freiburg, Germany).
Cell Culture
Rat glomerular MC were cultured as described previously (24) . All cell culture media and supplements were purchased from Life Technologies (Karlsruhe, Germany). The immunosuppressive agents whenever used were given in preincubations of 30 min before addition of the other agents.
Cytotoxicity Assay
Possible drug-induced cytotoxicity was measured by using the CytoTox96 Nonradioactive Cytotoxicity Assay (Promega, Mannheim, Germany).
SDS-PAGE Zymography
Assessment of gelatinolytic activity of proteins from cellular supernatants was performed as described previously (14) . Migration properties of proteins were determined by comparison with prestained full-range rainbow protein markers (Amersham Pharmacia Biotech).
cDNA Clones and Plasmids
cDNA inserts for rat MMP-9 and glyceraldehyde-3-phosphate dehydrogenase were generated as described recently (14) . A 1.3-kb fragment of the 5Ј-flanking region of the rat MMP-9 gene was cloned as described previously (15) . The plasmid pNFAT-Luc that contained the luciferase gene driven by a TATA box and ligated with four tandem repeats of NFAT binding sites was obtained from Stratagene (Mannheim, Germany).
Electrophoretic Mobility Shift Assay
Preparation of crude nuclear extracts from cultured MC and subsequent electrophoretic mobility shift assay (EMSA) was performed as described previously (25) . For supershift analysis, 2 l of supershift antibody was preincubated for 1 h at room temperature with the nuclear extracts before the binding reaction with the labeled oligonucleotides.
Northern Blot Analysis
Total cellular RNA was extracted from MC using the Tri reagent (Sigma-Aldrich Chemie), and RNA was hybridized following standard protocols as described previously (14) .
Western Blot Analysis
For detection of phosphorylated and total MAPK, whole-cell lysates were prepared as described previously (15) . Western blot analysis was performed by standard procedures.
A total of 50 g of crude nuclear cell extracts was used for the assessment of nuclear import of p65-NF-B. Cytoplasmic levels of IB were analyzed using 50 to 100 g of total protein from the corresponding cytoplasmic fractions. For ensuring an equal sample loading of nuclear proteins, the blots were stained with Ponceau-S.
Reporter Gene Assays
Transient transfections of MC with the wild-type-MMP-9 promoter construct were performed using the Effectene reagent (Qiagen, Hilden, Germany) as described previously (15) . Transfections were performed following the manufacturer's instructions. The transfections were done in triplicate and repeated at least three times to ensure reproducibility of the results. Transfection with pRL-CMV coding for Renilla luciferase was used for control of the transfection efficiency. Luciferase activities were measured with the dual reporter gene system (Promega) using an automated chemoluminescence detector (Berthold, Bad Wildbad, Germany).
Statistical Analyses
Results are expressed as means Ϯ SD. Statistical analysis was performed using the t test and the ANOVA test for significance. The data are presented as relative induction compared with control conditions or compared with IL-1␤-stimulated values. P Յ 0.05, Յ0.01, and Յ0.001 were considered significant, as appropriate.
Results
Cytokine-Induced Content of MMP-9 Is Differentially Affected by CsA and FK506
Initially, we evaluated possible modulatory effects of the two immunosuppressive agents CsA and FK506 on the gelatinolytic content of conditioned media of MC by zymography. As shown in Figure 1A , treatment of MC with IL-1␤ (2 nM) for 24 h caused an increase in latent MMP-9 levels that was characterized by a lytic band at 92 kD, whereas the constitutive levels of latent and active MMP-2 (corresponding to the lytic bands at 68 and 72 kD, respectively) remained unchanged ( Figure 1A ). Incubation with increasing concentrations of CsA (0.1, 1, and 5 M) caused a dosage-dependent reduction in the cytokine-induced MMP-9 content ( Figure 1A) . In contrast to CsA, FK506 showed no Figure 1 . Cyclosporin A (CsA) and FK506 differentially affect the cytokine-induced matrix metalloproteinase-9 (MMP-9) activity. Dosage-dependent modulation of the IL-1␤-induced gelatinase activity by CsA (A) or by FK506 (B and C). Quiescent mesangial cells (MC) were either left untreated (control) or treated for 24 h with IL-1␤ (2 nM) in the absence (ϩ vehicle) or presence of the indicated concentrations of CsA (A) and FK506, which was applied at two different concentration ranges (B and C). A total of 10 l of supernatant was subjected to SDS-PAGE zymography to assess the contents of extracellular MMP-9 (left). The migration properties of lytic bands, corresponding to inactive pro MMP-9 (92 kD), and the inactive and active forms of MMP-2 (72 and 68 kD) were determined using standard molecular weight markers. A statistical analysis of MMP-9 gelatinolytic activities derived from equal cell numbers and from three independent results is given at the right. Data are means Ϯ SD (n ϭ 3) and are presented as arbitrary units. *P Յ 0.05, **P Յ 0.01 versus control;
## P Յ 0.01 versus IL-1␤-treated conditions. significant effect on the cytokine-triggered MMP-9 content at low concentrations ( Figure 1B ) or higher concentrations ( Figure  1C ). To exclude that the inhibitory effects of CsA were due to cytotoxicity, we measured lactate dehydrogenase release. As shown in Table 1 , the survival rate of MC was Ͼ90% under all conditions tested, with no significant relation to the concentration of the immunosuppressive agent used for the experiments (Table 1) .
CsA Specifically Inhibits the Cytokine-Induced Steady-State mRNA Levels of MMP-9
To evaluate whether the reduction in the lytic content of MMP-9 by CsA was due to a decrease in the amount of MMP-9 mRNA levels, we performed Northern blot analysis. MC were stimulated for 24 h with IL-1␤ (2 nM) in the presence of vehicle (DMSO) or with various concentrations of CsA or FK506 as indicated in Figure 2 . CsA in contrast to FK506 significantly 
a Treatment-dependent (lactate dehydrogenase) release is expressed as the percentage of the total LDH release. ϩ indicates the cytotoxicity caused in combination with IL-1␤. Data are means Ϯ SD 24 h after stimulation with the indicated concentrations (n ϭ 3). Figure 2 . Modulation of IL-1␤-induced MMP-9 steady-state mRNA levels by CsA and FK506. Northern blot analysis demonstrating that a dosage-dependent inhibition of IL-1␤-induced MMP-9 is observed exclusively with CsA (A). Quiescent MC were stimulated with either vehicle (Ϫ) or IL-1␤ (2 nM; ϩ) for 24 h in the presence of the indicated concentrations of either CsA (A) or FK506 the latter of which was tested at two different concentration ranges (A and B). Total cellular RNA (20 g) was extracted and hybridized to a 32 P-labeled cDNA insert from KS-MMP-9 for analysis by Northern blot as described in Materials and Methods. Equivalent loading of RNA was ascertained by rehybridization to a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe. A statistical analysis of three independent experiments is shown in the bottom. Data are means Ϯ SD (n ϭ 3) and are presented as percentage of MMP-9 mRNA induced by IL-1␤.
## P Յ 0.01 versus IL-1␤-treated conditions. attenuated the cytokine-induced MMP-9 mRNA level, and again a maximum in the cytokine-stimulated MMP-9 mRNA levels is seen with 5 M CsA (Figure 2A) . Also, the higher concentrations of FK506 had no negative effect on MMP-9 mRNA levels, indicating that both calcineurin inhibitors have different effects on MMP-9 expression ( Figure 2B ). In view of the differences in the therapeutic dosage for the following experiments, FK506 was tested exclusively in the low concentration range (1 to 100 nM). CsA and FK506 when given alone had no significant effect on the basal MMP-9 mRNA content. These data indicate that the alterations of cytokine-induced zymogen activity by high dosages of CsA predominantly result from a reduction in the MMP-9 mRNA level.
Differential Modulation of Cytokine-Induced MMP-9 Promoter Activity by CsA and FK506
To evaluate further whether the changes in mRNA levels were attributed to a modulation of MMP-9 promoter activity by CsA, we performed reporter gene assays using a 1.3-kb MMP-9 promoter fragment ( Figure 3A ). This promoter portion is sufficient for the induction by IL-1␤ and critically depends on increased binding to AP-1 and NF-B promoter elements (14, 15) . MC were transiently transfected with pGL-MMP-9 (1.3 kb) and treated for 24 h with vehicle (control) or with IL-1␤ in the presence or absence of various concentrations of either CsA (0.1, 1, and 5 M) or FK506 (1, 10, and 100 nM) as indicated in Figure 3 . As shown in Figure 3B , the higher dosages of CsA (1 and 5 M) significantly prevented the cytokine-induced MMP-9 promoter activation ( Figure 3B ). In contrast, FK506 did not inhibit the IL-1␤-activated MMP-9 luciferase activity but instead caused a further increase in the cytokine-triggered MMP-9 promoter activity ( Figure 3C ).
CsA Specifically Interferes with NF-B and AP-1 Activities
Several studies could demonstrate that some of the antiinflammatory activities of CsA and FK506 are attributable to an inhibition of the transcription factors NF-B and AP-1. Both transcription factors are involved essentially in the transcriptional control of MMP-9 (15, 26) . To test for a possible involvement of either transcription factor in the CsA-mediated suppression of MMP-9, we assessed nuclear extracts from unstimulated cells (Ϫ) or from MC that were treated for 30 min with IL-1␤ (2 nM) and various concentrations of CsA ( Figure 5 ). The affinity of a slow-migrating and cytokine-inducible complex (C 1) and that of two faster migrating and constitutively bound complexes (C2 and C3) were attenuated by the higher dosages of CsA (1 and 5 M), whereas the lowest dosage of CsA tested (0.1 M) did not affect cytokine-induced DNA binding ( Figure 4A, left) . By contrast, FK506 had no effect on NF-B binding ( Figure 4A, right) . As demonstrated by the immunoreactivity of antibodies that were specific for NF-B/ p50 and NF-B/p65, binding of C1 is weakly affected by the anti-p50 antisera and totally abrogated by the anti-p65 antibody ( Figure 4B ). Conversely, complex C2 was strongly reduced by the anti-p50 antibody but only weakly affected by the anti-p65 antibody. Binding of complex C3 was not affected by any of the tested antibodies ( Figure 4B ). To test for a possible modulation of AP-1 by either immunosuppressant, we additionally tested the same nuclear extracts with gene-specific AP-1 oligonucleotide. Treatment of MC with IL-1␤ caused a moderate increase in the constitutive binding of one complex whose binding was reduced markedly when cells had been treated with the higher dosages of CsA (1 and 5 M; Figure 5A ). In contrast, reduction in DNA binding by FK506 was observed only with 100 nM ( Figure 5A ). Supershift analysis revealed that the AP-1-bound complex mainly consists of a heterodimeric complex of c-fos/c-jun and the strongest reduction in binding affinity is seen after the addition of an antibody that is raised specifically against a highly conserved DNAbinding domain of c-jun ( Figure 5B ). Collectively, these data indicate that in rat MC, in addition to modulation of NF-B binding, the cytokine-induced DNA binding to AP-1 is negatively influenced by CsA. In contrast, FK506 exerted only a weak inhibitory effect on AP-1 binding and had no suppressive influence on the cytokine-induced NF-B binding.
Inhibition of NF-B by CsA Is Paralleled by a Reduction in the Nuclear p65 Content
To test whether the CsA-mediated changes in NF-B DNA binding were attributable to a reduced translocation of NF-B, we performed Western blot analysis using nuclear fractions that were probed with a p65-specific antibody (27) . IL-1␤ caused a marked increase in the nuclear p65 content, and, in accordance with the data from EMSA, higher concentrations of CsA (1 and 5 M) caused a significant reduction in the cytokine-induced nuclear p65 content ( Figure 6A, top) . Concordant with EMSA, FK506 caused no significant changes in the cytokine-stimulated nuclear p65 level ( Figure 6A ).
Next, we tested for a possible effect on the NF-B inhibitor protein IB by either immunosuppressant. CsA, in a contrast to FK506, gradually prevented the disappearance of IB by IL-1␤, indicating that the decrease in the nuclear p65 content by CsA is caused by an inhibition of IB␣ degradation ( Figure 6B ). To elucidate further whether this increase in IB level by CsA is caused by an increased IB expression, we performed experiments with the protein synthesis inhibitor cycloheximide. Preincubation with cycloheximide did not affect the modulatory effects of CsA on IB, indicating that CsA does not interfere with the de novo synthesis of IB ( Figure 6C, left) . As a positive control, we added dexamethasone, which in rat MC can induce IB synthesis (15) . Addition of cycloheximide reversed the inhibitory effects on IB degradation that were caused by the glucocorticoid dexamethasone ( Figure 6C, right) .
Inhibitory Effects of CsA on MMP-9 Are Independent of NFAT-Mediated Pathways
Many of the immunomodulatory effects that are exerted by the calcineurin inhibitors CsA and FK506 critically depend on the interference with transcription factor NFAT and its target genes. Computer analysis revealed that the rat MMP-9 gene contains several putative NFAT binding sites, and expression of different NFAT isoforms in several nonimmune cells, including MC, has been demonstrated (28 -30) . The involvement of NFAT-dependent processes in the modulation of MMP-9 was tested by use of the VIVIT peptide, a highly specific NFAT inhibitor (31) . Treatment of MC in the presence of this inhibitor did not attenuate the cytokine-induced gelatinolytic activity in MC supernatants ( Figure 7A, left) . Consistently, reporter gene assays revealed that an ionomycin-inducible NFAT reporter construct is not induced by IL-1␤ and also is not modulated by CsA or FK506 ( Figure 7A, right) . Furthermore, the low basal content of nuclear NFAT remained unchanged independent of the stimulus used ( Figure 7B, left) . By contrast, a clear nuclear translocation of NFAT is elicited by the Ca 2ϩ ionophore ionomycin, indicating that the Ca 2ϩ /calcineurin-dependent activation of NFAT is operative in rat MC ( Figure 7B, left) . To evaluate whether both drugs would display a different immunosuppressive potential in MC, we compared their NFATinhibitory activity at the lowest concentration (10 nM). Similar to the NFAT inhibitor that was used as a positive control, FK506 exerted a strong inhibitory effect on the ionomycininduced NFAT accumulation within nuclear fractions. By contrast, CsA at the same concentration had no inhibitory effect on NFAT activation ( Figure 7B, right) . These results indicate that the inhibitory effects on MMP-9 by CsA are not related to NFAT inhibition.
CsA Specifically Interferes with the Cytokine-Induced Activity of MAPK
Finally, we tested the impact of MAPK on the content of cytokine-induced extracellular MMP-9. In glomerular MC, activation of these kinases is achieved by a stimulation with IL-1␤ (14, 32) . It is interesting that PD98059, an inhibitor of the p42/ p44 MAPK, further amplified the cytokine-induced MMP-9, whereas SB203580, an inhibitor of the p38 pathway, had no effect on the extracellular MMP-9 content ( Figure 8A ). By contrast, JNK inhibitor SP600125 strongly reduced the cytokinetriggered MMP-9 level ( Figure 8A ). Using phospho-specific antibodies, we furthermore found that the cytokine-induced phosphorylation of ERK and JNK is blocked by CsA, although with a different potency ( Figure 8B ). Whereas phosphorylation of JNK is affected only with higher CsA concentrations (1 and 5 M), the level of phosphorylated ERK is attenuated already with the lowest CsA concentration used (0.1 M). Because CsA had no effect on total MAPK levels, the changes in the contents of phosphorylated MAPK are not attributable to alterations in the total contents of MAPK ( Figure 8B ). By contrast, FK506 had p65 (A, left) . For Western blot analysis, nuclear extracts (50 g) were immunodetected with an anti-p65 antibody. Loading of equal amounts of nuclear extract was ascertained by Ponceau-S (P.S.) staining. In contrast, treatment with FK506 had no inhibitory effect on the cytokineevoked increase in the nuclear p65 contents (A, right). A statistical analysis of three independent results is given at the bottom. Data are means Ϯ SD (n ϭ 3) and are represented as arbitrary units. **P Յ 0.01 versus control; # P Յ 0.05, ## P Յ 0.01 versus IL-1␤-treated conditions. Concomitant to the modulation in p65, the IL-1␤-mediated degradation of cytoplasmic IB is differentially affected by CsA (B, left) and FK506 (B, right). A total of 100 g of protein lysates from corresponding cytoplasmic fractions from the same experiments that were used for isolation of nuclear extracts were subjected to SDS-PAGE and immunoblotted using an anti-IB␣-specific polyclonal antibody. For correction for variations in the protein loading, the blots were reprobed with an anti-␤-actin antibody. Influence of cycloheximide on CsA (C, left) or dexamethasone (Dex; C, right) triggered modulation of the IL-1␤-induced IB degradation. MC were left untreated (Ϫ) or were treated for 30 min with 2 nM IL-1␤ (ϩ) either alone or in the presence of 1.0 M CsA or 100 nM Dex. Alternatively, MC additionally were treated in the presence of the protein synthesis inhibitor cycloheximide (10 g/ml), which was added 30 min before stimulation with CsA or Dex. Data were similar in two additional and independent experiments. no inhibitory effects on cytokine-triggered ERK or JNK phosphorylation ( Figure 8C ). These data may indicate that CsA, by preventing JNK activation, negatively interferes with cytokineinduced MMP-9 expression.
Discussion
Our study aimed to compare the modulatory effects of two prominent immunosuppressive agents, CsA and FK506, on the cytokine-induced MMP-9 expression in glomerular MC, because CsA in many cases exerts a higher fibrogenic potential when compared with FK506 (23). Accordingly, comparison of the outcome in renal transplantations has indicated a clearly improved long-term graft survival when FK506 was administered instead of CsA (23, 33) . The underlying molecular mechanisms of CsA-mediated nephrotoxicity are not fully understood, and various studies have suggested that primarily a imbalance in the protease-antiprotease system is responsible for the drug-induced tubulointerstitial fibrosis (34) . We chose MC as a cell culture model system because chronic CsA nephrotoxicity is not only reflected by tubular atrophy and interstitial fibrosis but also characterized by a massive expansion of mesangial ECM. In addition to tubular toxicity, CsA has glomerular adverse effects. Moreover, calcineurins are known to play an important role in glomerular hypertrophy and ECM A total of 50 g of lysate was subjected to SDS-PAGE and successively immunoblotted with the phosphorylation state-specific antibodies against the indicated MAPK. For ascertainment that the total level of each MAPK remained unchanged, blots were stripped and reprobed with the antibodies raised against the corresponding phosphorylation-independent MAPK. The data are representative of three independent experiments that gave similar results. accumulation in diabetic nephropathy (35) . Mechanistically, besides increased expression of protease inhibitors, members of the MMP family are critically involved in the increased matrix deposition, and, particularly, downregulation of MMP-9 has been found to be involved in CsA-induced nephrosclerosis (34) . Accordingly, MMP-9 is a protease that is supposed to play a key role in the pathogenesis of renal fibrosis (14, 36) . In this study, we demonstrate that CsA, in contrast to FK506, dosagedependently suppressed the cytokine-induced MMP-9 via an inhibition in MMP-9 gene expression and independent of NFAT inhibition. Regulation of MMP-9 transcription by IL-1␤ critically depends on the activation of NF-B and AP-1 transcription factors (14 -16) . In this study, we demonstrate that inhibition of MMP-9 expression by CsA is associated with an inhibition of NF-B and AP-1, whereas FK506 had no effect or weak effects on these transcription factors. In line with these observations, many of the anti-inflammatory effects that are exerted by the calcineurin inhibitors have been ascribed to the inhibitory effect on cytokine-induced NF-B activation (9, 22) . Up to now, only fragmentary data on how CsA may affect NF-B-p65 nuclear translocation have been available, and a variety of mechanisms have been envisaged. We show that the CsA-dependent inhibition of NF-B DNA binding is caused by a sequestration of NF-B in the cytoplasm, thereby impeding the IL-1␤-caused translocation into the nucleus. A CsA-dependent NF-B suppression via direct inhibition of the chymotrypsin-like activity of the 20S proteasome that is necessary for LPS-induced IB degradation was shown by a study of Meyer et al. (37) . Searching for specific CsA target pathways that act upstream of the NF-B-and AP-1-driven transcription of MMP-9 in MC, we found a negative interference of CsA with the IL-1␤-induced JNK activity. The CsA-dependent inhibition of this MAPK pathway is partially compatible with studies from T cells that demonstrated an inhibition of JNK and p38 signaling pathways by CsA and FK506 via calcineurin-independent mechanisms, indicating that these MAPK allegorize an additional target of immunosuppressive actions of both agents (38) . Activation of JNK can modulate gene expression through phosphorylation of various kinds of transcription factors, including AP-1 (18, 38) . Notably, inhibition of cytokine-induced MAPK activities in MC is found exclusively with CsA, and CsA in addition to interfering with the JNK affects the mitogenactivated ERK. This is in a certain discrepancy to the CsAdependent inhibition of T cell activation that is restricted to the p38 and JNK and that points to a cell type-specific mechanism (38) . In this context, it is worth noting that mitogen-activated protein/ERK kinase kinase is involved in both JNK and NF-B pathways, suggesting that a negative interference with CsA at the level of the mitogen-activated protein/ERK kinase kinase may account for the CsA-sensitive NF-B inhibition that is observed in lymphoid and several nonlymphoid cells (38) . Further studies are needed to determine which signaling cascade upstream from MAPK and independent of calcineurin is targeted by CsA in renal MC. Here we show that direct and specific modulation of MMP-9 expression by CsA is paralleled by a specific inhibition of JNK. Our findings furthermore suggest that independent of their immunosuppressive potency, both drugs selectively affect the balance of the MMP-9/tissue inhibitor of MMP-1 system and therefore confer different fibrotic activities. The understanding of drug-induced effects on matrix turnover may conceive the increased risk for fibrotic adverse effects that have been reported for CsA and furthermore underlines the beneficial role of FK506.
